Understanding Patterns of Missingness in Acute Ischemic Stroke Trials: A Secondary Analysis of Pooled Participant-Level Follow-Up Data

Adam De Havenon*, Aaron Bangad, Lesli E. Skolarus, Chad M. Aldridge, Robynne G. Braun, John W. Cole, Steven C. Cramer, Arne G. Lindgren, N. Abimbola Sunmonu, Bradford B. Worrall, Keith R. Lohse

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)E201-E202
JournalStroke
Volume54
Issue number5
DOIs
StatePublished - May 1 2023

Funding

Dr de Havenon receives research funding from the National Institutes of Health (NIH), consultant fees from Integra and Novo Nordisk, royalty fees from UpToDate, and equity in TitinKM and Certus. Dr Cramer serves as a consultant for Abbvie, Constant Therapeutics, MicroTransponder, Neurolutions, SanBio, Panaxium, NeuExcell, Elevian, Medtronic, Helius, Omniscient, and TRCare. Dr Lindgren reports personal fees from Bayer, NovoNordisk, Astra Zeneca, and BMS Pfizer. Dr Skolarus reports research funding from NIH and American Heart Association, and employment by University of Michigan and Northwestern. The other authors report no conflicts.

Keywords

  • albumin
  • ethnicity
  • hyperglycemia
  • ischemic stroke
  • odds ratio

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this